Pulmonary embolism, coagulation

Version vom 11. Juni 2020, 09:47 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

Since there are many organ manifestations of Hypercoagulation, subcategorization and tranccategorization was applied.

• Venous thrombosis
• Pulmonary embolism
• Cerebral embolism
• Myocardial infarction
• Arterial embolism
• Microembolism
• Hypercoagulation
• Antiphospholipid antibodies
• Disseminated intravascular coagulation
• Bleeding
• Labwork of Thrombembolism
• Prophylaxis of Thrombembolism

The unifying concept behind is Dysendoheliosis with the components Coagulation /Microthrombi, proliferative or cytopathic obstructive Endotheliosis and mediator production as well as failure of the mitigating systems and secondary vasculitis.

• thrombotic late reactions

32360432 ä. Acute thrombosis of an aortic prosthetic graft in a patient with severe COVID-19 related pneumonia
32335249 ä. SARSCoV-2 infection and the upper limbs deep vein thrombosis risk
32350161 2020. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China
32281926 2020. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)
32250159 2020. Hemorrhagic Problem Among the Patients With COVID-19: Clinical Summary of 41 Thai Infected Patients
32357997 2020. Coagulopathy associated with COVID-19
32334995 2020. Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia

32338707 ä. Acute pulmonary embolism in conjunction with intramural right ventricular thrombus in a SARS-CoV-2-positive patient

32367170 ä. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study
32347323 ä. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation

32322918 ä. Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening

32311448 ä. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
32212240 2020. Disseminated intravascular coagulation in patients with 2019?nCoV pneumonia
32073213 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

32367471 ä. Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies
32338320 ä. Covid-19 treatment update: follow the scientific evidence
32246317 ä. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2
32306290 ä. Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report

32360371 ä. Thromboembolic events in patients with SARS-CoV-2
32360679 ä. Acute limb ischemia in patients with COVID-19 pneumonia
32305586 ä. Upsurge of deep venous thrombosis in patients affected by COVID-19: Preliminary data and possible explanations
32360372 ä. An increased severity of peripheral arterial disease in the covid-19 era
32361070 2020. Cardiovascular examination should also include peripheral arterial evaluation for COVID-19 patients

32330428 ä. Hospital-based use of thromboprophylaxis in patients with COVID-19
32268022 ä. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

32351657 ä. Arterial and venous abdominal thrombosis in a 79-year-old woman with COVID-19 pneumonia
32353746 2020. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy
32335420 ä. Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients

32361513 ä. Where do we stand with antithrombotic prophylaxis in patients with COVID-19?

C7146714 ä. Incidence of thrombotic complications in critically ill ICU patients with COVID-19

32267008 2020. Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability
32374815 ä. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

32339221 2020. COVID-19 and its implications for thrombosis and anticoagulation
32374029 2020. Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis
32369614 2020. Concomitant haemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukaemia

32353183 2020. Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19

32304577 2020. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action
32352633 2020. Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients
32339025 2020. Why Fibrinolytic Therapy for STEMI in The COVID-19 Pandemic is Not Your New Best Friend

32172226 2020. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection
32333581 2020. Contrast enhanced ultrasonography (CEUS) to detect abdominal microcirculatory disorders in severe cases of COVID-19 infection: First experience
32333579 2020. (clin-hemorheol-microcirc) COVID-19

32311843 2020. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2

32379935 2020. Response to "Lupus anticoagulant is frequent in patients with Covid-19"
32379918 2020. Coagulopathy of COVID-19 and antiphospholipid antibodies
32369666 2020. Incidence of venous thromboembolism in hospitalized patients with COVID-19
32239799 2020. The versatile heparin in COVID-19
32338827 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19
32302462 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment
32302442 2020. RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19
32220112 2020. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
32302451 2020. Response to Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
32302438 2020. Hypercoagulability of COVID-19 patients in Intensive Care Unit A Report of Thromboelastography Findings and other Parameters of Hemostasis
32271988 2020. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia
32344457 2020. Uncertainties on the prognostic value of D-dimers in COVID-19 patients

32329221 2020. Type and dose of heparin in Covid-19: Reply
32329246 2020. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19
32324960 2020. Laboratory haemostasis monitoring in COVID-19
32324958 2020. Lupus anticoagulant is frequent in patients with Covid-19
32320517 2020. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients
32306492 2020. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19
32302459 2020. COVID-19 and acute coagulopathy in pregnancy
32302453 2020. Thromboinflammation and the hypercoagulability of COVID-19

32294321 2020. Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis

32294289 2020. Venous thromboembolism in COVID-19 patients

32282993 2020. DOACs and newer haemophilia therapies in COVID-19
32281766 2020. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?

32359410 ä. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT
32369280 ä. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

32367765 2020. Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count
32367749 2020. Transient appearance of EDTA dependent pseudothrombocytopenia in a patient with 2019 novel coronavirus pneumonia

32324101 2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands

32324099 2020. Pulmonary, Cerebral, and Renal Thromboembolic Disease Associated with COVID-19 Infection
32374544 2020. Risque thrombotique veineux induit par le SARS-CoV-2 : prevalence, recommandations et perspectives
32378030 ä. COVID-19-Related Stroke
32279286 2020. Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring
32349133 2020. Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge
32349132 2020. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?
32316065 2020. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines
32316063 2020. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure
32374920 2020. Viscoelastic testing in COVID-19: a possible screening tool for severe disease?
32220276 2020. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia
32133825 2020. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19
32133824 2020. COVID-19 complicated with DIC: 2 cases report and literatures review
32283877 2020. Prognostic value of myocardial injury in patients with COVID-19
32344469 2020. DIC in COVID-19: Implications for Prognosis and Treatment?
32267998 2020. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series
32378044 ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment

32418867 ä. COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept
C7196387 ä. Extensive aortic thrombosis in a patient with Covid-19

32414639 ä. Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern?

32378044 ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment

C7183940 ä. Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19
32402423 2020. Ten key points that vascular doctors learned very quickly about COVID-19
32417015 ä. Risk of peripheral arterial thrombosis in COVID-19
32423583 2020. Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19

C7177114 2020. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes
32376101 2020. Association Between Hypoxemia and Mortality in Patients With COVID-19
32474397 2020. Venous thromboembolism and COVID-19

32407937 2020. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China
32403032 2020. Early thromboembolic events in hospitalized COVID-19 patients

32381264 2020. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis
32388068 2020. Thrombotic complications in critically ill patients with COVID 19
32291094 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19